First-in-class oral ERK1/2 inhibitor Ulixertinib (BVD-523) in patients with advanced solid tumors: Final results of a phase I dose escalation and expansion study Meeting Abstract
| Authors: | Li, B. T.; Janku, F.; Patel, M. R.; Sullivan, R. J.; Flaherty, K.; Buchbinder, E. I.; Lacouture, M. E.; Varghese, A. M.; Wong, D. J. L.; Sznol, M.; Sosman, J. A.; Keedy, V. L.; Wang-Gillam, A.; Ribas, A.; Tolcher, A. W.; Patel, S. P.; Varterasian, M. L.; Welsch, D.; Hyman, D. M.; Infante, J. R. |
| Abstract Title: | First-in-class oral ERK1/2 inhibitor Ulixertinib (BVD-523) in patients with advanced solid tumors: Final results of a phase I dose escalation and expansion study |
| Meeting Title: | 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 35 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2017 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2017-05-20 |
| Start Page: | 109s |
| Language: | English |
| ACCESSION: | WOS:000411895704111 |
| DOI: | 10.1200/JCO.2017.35.15_suppl.2508 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 2508 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
